Category: Refractory Cancer & Precision Oncology Care
When cancer does not respond to surgery, chemotherapy, or targeted therapy: medical options that still exist
ไทย · English
· ☕ Buy me a coffee
When cancer stops responding to standard surgery, chemotherapy, or targeted therapy, current medical next steps center on deep genomic testing
(NGS / comprehensive genomic profiling)
to find rare targetable mutations, immunotherapy biomarkers (MSI-H / TMB), and
clinical trials
of newer modalities such as ADCs or CAR-T — plus a Multidisciplinary Tumor Board second look and palliative care to protect quality of life.
Red flags — contact your team now
- Pain that suddenly worsens or is no longer controlled by current medicines
- Shortness of breath, chest pressure, or symptoms that may signal thromboembolism
- High fever during or after chemotherapy — especially with low white-cell counts (neutropenic fever)
- New neurologic signs: numbness, weakness, severe headache, or seizure
- Unusual bleeding, vomiting blood, or black/bloody stools
- Severe weakness, inability to drink, or confusion — may reflect dehydration, infection, or kidney failure
1. What refractory cancer means — and why NGS matters
Refractory cancer means the tumor does not shrink, stabilize, or stay controlled despite standard treatments such as surgery, chemotherapy, and targeted therapy.
Per
NCI — Precision Medicine,
that does not always mean “no options left” — it means the strategy should shift toward precision oncology.
Older limited gene panels often covered only a few genes (for example EGFR or ALK in lung cancer).
Next-generation sequencing (NGS), or comprehensive genomic profiling, can analyze hundreds of genes at once to find
rare targetable mutations that the original plan never tested.
Scientific mechanism
Cancer cells accumulate somatic mutations that drive growth and drug resistance.
NGS reads DNA/RNA from tissue or, in some cases, blood (liquid biopsy), then matches findings to drug and guideline databases.
If a fusion, amplification, or mutation has a matching targeted agent or immunotherapy pathway — including some tumor-agnostic indications — the team may change therapy.
Interpretation belongs to a precision-oncology team, not the raw report alone.
Mechanism summary by
Asst. Prof. Dr. Norawit Raatpiboon
· Cite
PubMed — Comprehensive genomic profiling
Table: next-step medical options for refractory cancer
| Approach / technology | Mechanism & detail | Who it may fit | Treatment goal |
|---|---|---|---|
| NGS / comprehensive genomic profiling | Broad tumor gene profiling for targetable mutations, fusions, TMB | After standard therapy, with adequate tissue or blood sample | Open new targeted or immunotherapy options |
| Immunotherapy biomarkers (MSI-H/dMMR, TMB-High) | Estimate sensitivity to PD-1/PD-L1 immune checkpoint inhibitors | Never tested, or progressive disease after targeted therapy | Engage the immune system against cancer cells |
| Clinical trials (ADCs, bispecifics, CAR-T) | Investigational or newly approved modalities under protocol | Refractory/relapsed patients who meet eligibility criteria | Control or stabilize disease when standards fail |
| Multidisciplinary Tumor Board (MDT) | Cross-specialty review of history, imaging, and genomics | Complex multi-line cases or second-opinion needs | Reduce blind spots; sequence care rationally |
| Integrative palliative care | Symptom, nutrition, and psychosocial support beside active therapy | Any stage with quality-of-life burden | Keep the body strong enough for further treatment |
Optional digestive-symptom check-in
Analyze severity and get personalized guidance from our Advisory team
Take the free cancer-care urgency assessment
This tool does not diagnose cancer. Unexplained weight loss, persistent bleeding, or suspected malignancy need urgent medical evaluation.
2. Clinical trials and newer modalities (ADCs / bispecifics)
After standard options are exhausted,
clinical trials
are a structured next path — not “underground medicine,” but protocol-based care with close monitoring.
Antibody-drug conjugates (ADCs)
ADCs link an antibody to a chemotherapy payload so the drug preferentially enters cancer cells that display a target antigen.
Compared with conventional systemic chemotherapy, off-tumor exposure can be lower in some settings — use is limited to matching cancer types and biomarkers.
Bispecific antibodies and CAR-T cell therapy
Bispecific antibodies engage both cancer cells and immune cells to redirect killing.
CAR-T engineers the patient’s T cells to recognize a chosen antigen — most established in selected blood cancers, with expanding research in solid tumors.
Access in Thailand
Ask research oncology units at university hospitals (for example Chulalongkorn, Siriraj, Ramathibodi) or the National Cancer Institute.
Teams screen performance status, labs, and prior therapy before offering a matching protocol.
→
Consult oncology / Tumor Board
→
Eligibility screening
→
Enroll + follow protocol visits
3. Immunotherapy biomarkers: MSI-H and TMB-High
If tissue has never been tested for
MSI (microsatellite instability) / dMMR
or TMB (tumor mutational burden),
ask about additional testing per
NCI — Biomarker Testing.
- MSI-H / dMMR: often linked to stronger responses to immune checkpoint inhibitors across several cancers (including some tumor-agnostic indications)
- TMB-High: a high mutation load may make tumor cells more visible to the immune system — see
PubMed — TMB and immunotherapy - PD-L1 expression: used with certain cancer types (for example NSCLC) when deciding on checkpoint-inhibitor therapy
Biomarker testing before decisions helps avoid ineffective drugs and unnecessary toxicity.
4. Tumor Board (MDT) and palliative care
Multidisciplinary Tumor Board
A Tumor Board brings medical oncology, radiation oncology, surgery, pathology, and allied specialties together to review the full treatment history, imaging, and genomic results.
That reduces blind spots after multiple prior lines of care.
Asking for a second opinion at a leading university cancer center is a reasonable step — not a rejection of your current team.
Palliative care — not “giving up”
Per
NCI — Palliative Care,
palliative care focuses on pain, fatigue, nausea, bloating, and nutrition so patients live better and stay fit enough for further therapy (including trials).
Start it alongside active treatment — do not wait for an “end-stage only” moment.
Coordinating palliative care with oncology often improves balance between disease-directed therapy and day-to-day quality of life.
Comparison table: clinical trial access vs standard care
| Comparison point | Standard care | Clinical trials |
|---|---|---|
| Evidence base | Phase III data and clear guideline pathways | Phase I–III data; some evidence still limited — monitoring is intensive |
| Patient criteria | Broader, by labeled indication | Narrowed by protocol eligibility criteria |
| Cost / coverage | Depends on insurance and hospital policy | Study drug often provided; other costs vary by protocol |
| Follow-up intensity | Per treating oncologist’s plan | Mandatory labs/imaging on protocol schedule |
| When disease is refractory | Switch available chemo/targeted regimens or best supportive care | Access ADCs, bispecifics, CAR-T, or new combinations |
| Unknown risks | Lower — side effects better characterized | May be higher in early-phase trials |
This table is a general comparison frame — it does not replace consultation with your oncologist or hospital research team.
Scientific mechanism (author summary)
By Asst. Prof. Dr. Norawit Raatpiboon:
Refractory disease often reflects clonal evolution — surviving clones carry mutations or pathway rewiring that escape prior surgery, chemotherapy, or targeted agents.
Broad NGS maps those drivers; MSI-H/dMMR and TMB-High flag tumors more likely to respond to immune checkpoint blockade; ADCs and engineered immune modalities attack antigen-defined populations under trial or labeled rules.
Parallel palliative care stabilizes symptoms so patients can tolerate the next line.
FAQ
When cancer does not respond to surgery, chemotherapy, and standard targeted therapy, what should happen next?
Typical steps: (1) re-review pathology and full treatment history,
(2) complete NGS / biomarkers not yet done,
(3) seek Tumor Board or second opinion,
(4) screen for clinical trials,
(5) start or intensify palliative care in parallel.
How does NGS help find new options?
NGS may reveal mutations that unlock targeted therapy or immunotherapy not in the original plan,
including some agnostic indications — results require precision-oncology interpretation.
How do patients join clinical trials?
Oncology or research centers screen eligibility using NGS reports, labs, and performance status.
If one protocol does not fit, another may.
What is palliative care’s role in refractory disease?
It controls symptoms and restores energy so quality of life improves and further therapy remains possible —
it does not automatically mean stopping cancer treatment.
Why do MSI-H and TMB-High matter?
They help estimate the chance of benefit from immune checkpoint inhibitors.
Test when never done, or when the tumor changes after therapy.
Should herbal or unregulated remedies be avoided?
Yes — contaminants can injure liver or kidney function or interact with cancer drugs.
Disclose every product and avoid claims of guaranteed cure.
Refractory vs relapsed — what is the difference?
Refractory usually means little response from the start or during therapy.
Relapsed means disease returned after response or remission.
NGS and trial pathways often apply to both; details depend on cancer type.
Support this writing
If this roadmap clarified NGS, trials, and palliative care after standard therapy stopped working, a coffee-sized donation keeps free, cited explainers online in Thai and English.
E-E-A-T & academic citations
- NCI — Precision Medicine in Cancer Treatment
- NCI — Biomarker Testing for Cancer Treatment
- NCI — Clinical Trials Information
- PubMed — Tumor mutational burden and immunotherapy
- PubMed — Comprehensive genomic profiling in advanced cancer
- NCI — Palliative Care in Cancer
Written and reviewed by
Asst. Prof. Dr. Norawit Raatpiboon
(ผศ.ดร.นรวิชญ์ ราษฎร์พิบูลย์)
Medical disclaimer
This article is general education on refractory cancer and precision oncology.
It is not individualized diagnosis, prescribing, or a treatment order.
Decisions about NGS, immunotherapy, clinical trials, or palliative care must be made with your oncology team and hospital.
For emergency red-flag symptoms, contact your physician or an emergency department immediately.